| Outcome Measures: |
Primary: effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature, The primary objective of the study is the change of renal plasma flow to LNMMA infusion from baseline (given in ml/min) to determine the effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature., Changes from baseline after 4 weeks of treatment with linagliptin and placebo | Secondary: effects of linagliptin compared to placebo on other renal hemodynamic parameters, Renal plasma flow, glomerular filtration rate and filtration fraction, renal vascular resistance, calculated intraglomerular pressure., Changes from baseline after 4 weeks of treatment with linagliptin and placebo|effect of linagliptin compared to placebo on urinary albumin creatinine ratio and tubular markers (e.g. NGAL)., effect of linagliptin compared to placebo on urinary albumin creatinine ratio and tubular markers (e.g. NGAL)., Changes from baseline after 4 weeks of treatment with linagliptin and placebo|effect of linagliptin compared to placebo on markers of oxidative stress (e.g. isoprostanes) and inflammation (e.g. hsCRP)., effect of linagliptin compared to placebo on markers of oxidative stress (e.g. isoprostanes) and inflammation (e.g. hsCRP)., Changes from baseline after 4 weeks with linagliptin versus placebo|effect of linagliptin compared to placebo on metabolic parameters (fasting glucose, fasting insulin, triglycerides, total-, LDL- and HDL-cholesterol), effect of linagliptin compared to placebo on metabolic parameters (fasting glucose, fasting insulin, triglycerides, total-, LDL- and HDL-cholesterol), Changes from baseline after 4 weeks of treatment with linaplitpin and placebo|effect of linagliptin compared to baseline on the change of renal plasma flow due to L-NMMA-infusion, effect of linagliptin compared to baseline on the change of renal plasma flow due to L-NMMA-infusion, Changes from baseline after 4 weeks of treatment with linagliptin and placebo|effects of linagliptin compared to baseline on other renal hemodynamic parameters, effects of linagliptin compared to baseline on other renal hemodynamic parameters: Renal plasma flow, glomerular filtration rate and filtration fraction, renal vascular resistance, calculated intraglomerular pressure, Changes from baseline after 4 weeks of treatment with linagliptin and placebo|of linagliptin compared to baseline on urinary albumin creatinine ratio and tubular markers (e.g. NGAL), of linagliptin compared to baseline on urinary albumin creatinine ratio and tubular markers (e.g. NGAL), Changes from baseline after 4 weeks of treatment with linagliptin and placebo|effect of linagliptin compared to baseline on markers of oxidative stress (e.g. isoprostanes) and inflammation (e.g. hsCRP)., effect of linagliptin compared to baseline on markers of oxidative stress (e.g. isoprostanes) and inflammation (e.g. hsCRP), Changes from baseline after 4 weeks of treatment with linagliptin and placebo|effect of linagliptin compared to baseline on metabolic parameters (fasting glucose, fasting insulin, triglycerides, total-, LDL- and HDL-cholesterol), effect of linagliptin compared to baseline on metabolic parameters (fasting glucose, fasting insulin, triglycerides, total-, LDL- and HDL-cholesterol), Changes from baseline after 4 weeks of treatment with linagliptin and placebo|determine the relationship between changes of renal endothelial function with metabolic changes and changes of isoprostanes, determine the relationship between changes of renal endothelial function with metabolic changes and changes of isoprostanes, Changes from baseline after 4 weeks of treatment with linagliptin and placebo
|
| Locations: |
Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, 91054, Germany|Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Nuremberg, 90471, Germany
|
